biotech · Cervical Spinal Cord Injury · Spinal Cord Injury · LCTX
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a biotech organization headquartered in Carlsbad, USA. It trades on NYSE under ticker LCTX. Primary therapeutic focus areas include Cervical Spinal Cord Injury, Spinal Cord Injury, Spinal Cor
Carlsbad, USA HQ
1990 Founded
35 Employees
Public company Type
LCTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Carlsbad, USA
- Founded
- 1990
- Employees
- 35
- Programs
- 3
- Drugs
- 0
- Patents
- 0
AST-OPC1
Phase 2 · mab · Cervical Spinal Cord Injury
AST-OPC1 for Cervical Spinal Cord Injury is a Phase 2 program (mab) at Lineage Cell Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code AST-OPC1-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lineage Cell Therapeutics
- Phase
- Phase 2
- Modality
- mab
- Indication
- Cervical Spinal Cord Injury
- Status
- completed
- Trials
- 1